SOAP Note Template for Aesthetic and Wellness Practices

What each section holds in an aesthetic or wellness visit

Two habits separate a usable chart from a liability. Assessment must contain a judgment, not a restatement of the request: "patient requests Botox" is not an assessment, while "appropriate candidate for glabellar neuromodulation, no neuromuscular disorder, not pregnant" is. And everything in Plan should be specific enough that another clinician could reproduce the treatment from the note alone.

A blank SOAP template you can copy

Date and time of service. Provider name and credentials. Supervising or collaborating prescriber where applicable.

S — Subjective Chief concern in the patient's words. Interval changes since the last visit. Current medications, supplements and allergies. Response to the previous treatment, including onset, peak and duration. Aftercare compliance. Pregnancy or breastfeeding status. Recent illness, dental work or anticoagulant use where relevant.

O — Objective Vitals if taken. Weight, BMI or measurements if relevant. Skin type and condition. Physical findings, including muscle strength, asymmetry, volume loss, and lesions or bruising present before treatment. Photographs taken, with standardized views and lighting. Device parameters and observed skin endpoint.

A — Assessment Aesthetic or clinical impression. Candidacy statement. Contraindications reviewed and excluded. Any change from the good faith exam or original plan, with reasoning.

P — Plan Consent confirmed, form name and date. Product or device, manufacturer, lot number, expiration date. Dilution or concentration if reconstituted. Total units or volume administered. Site-by-site breakdown with amounts and injection depth or plane. Needle or cannula gauge. Anesthetic used. Patient tolerance and any immediate reaction. Post-treatment observations. Aftercare instructions given, by name, plus copy provided. Next appointment or follow-up window. Escalation criteria and after-hours contact. Signature and time.

Worked example one, neurotoxin visit

Date and time. August 24, 2026, 10:15 to 10:40. Provider: J. Alvarez, RN, injecting under the direction of Dr. M. Reyes, MD, per patient-specific order dated August 18, 2026.

S. Patient is a 34-year-old female returning for neuromodulator treatment of glabellar and lateral canthal lines. Reports her last treatment on May 2, 2026 took effect around day 5, peaked at week 2, and began to soften at week 12. Satisfied with the previous result and asks for slightly more movement retained in the forehead. Denies headache, ptosis or diplopia after the last session. No new medications; takes a daily multivitamin. No aminoglycosides. NKDA. Denies pregnancy or breastfeeding; last menstrual period August 12. Denies neuromuscular disorder.

O. BP 118/74, HR 68. Fitzpatrick III. Moderate dynamic glabellar rhytids at maximum frown, moderate dynamic lateral canthal rhytids at full smile, mild static forehead lines at rest. Brow position symmetric, no baseline ptosis. Mild pre-existing left brow elevation shown to the patient in the mirror. No active lesions or infection at planned sites. Standardized photographs at rest and in animation, frontal and both obliques.

A. Appropriate candidate for repeat neuromodulation of glabellar complex and lateral canthal lines. No contraindications identified. Pre-existing left brow asymmetry documented and discussed. Treatment plan adjusted to reduce frontalis dosing per patient preference for retained movement.

P. Consent confirmed; procedure-specific neurotoxin consent signed August 24, 2026 before treatment, copy given. Product: onabotulinumtoxinA 100-unit vial, lot 7C42193, expiration 03/2028. Reconstituted with 2.5 mL preserved 0.9% sodium chloride at 09:50, yielding 4 units per 0.1 mL. Skin cleansed with alcohol; no topical anesthetic. 32-gauge needle, changed after every four injection points.

Units administered, total 52:

Glabellar and frontalis injections intramuscular; lateral canthal injections superficial, at least 1 cm lateral to the orbital rim. Frontalis dosing reduced from the prior visit at the patient's request to retain movement, 2 units per site rather than 4. Patient tolerated the procedure well, reported pain 2 out of 10. Pinpoint bleeding at two sites, resolved with pressure. No immediate adverse reaction. Observed 5 minutes post-treatment, no dizziness or visual change.

Aftercare: "Neurotoxin Aftercare Card" given and reviewed, remain upright 4 hours, no rubbing or massage of treated areas and no strenuous exercise for 24 hours, no facials or heat exposure for 2 weeks. Advised onset 3 to 7 days, full effect at 2 weeks, two-week follow-up offered for possible touch-up. Instructed to call immediately for eyelid drooping, double vision, difficulty swallowing or breathing, or spreading weakness; after-hours number given. Next treatment anticipated in 12 to 14 weeks. Signed J. Alvarez, RN, August 24, 2026, 10:44.

Worked example two, GLP-1 weight-loss follow-up

Date and time. August 24, 2026, 14:00 to 14:20. Telehealth video visit. Provider: K. Osei, NP. Patient located in-state at home address on file; identity confirmed by photo ID.

S. 47-year-old female, week 8 of a medically supervised weight-management program on semaglutide. Currently 0.5 mg weekly, last dose August 21. Reports mild nausea on days 1 and 2 after each injection, resolving without medication, and early satiety with smaller portions. Denies vomiting, severe abdominal pain, right upper quadrant pain, or persistent constipation. Reports 3 days per week of walking, 30 minutes, and consistent protein intake at breakfast. Adherent to all 8 weekly doses. Denies personal or family history of medullary thyroid carcinoma or MEN 2. Not pregnant, on contraception. No new medications.

O. Home scale weight 214 lb, down from 227 lb at baseline, a 5.7% reduction over 8 weeks. Self-reported BP 126/80 with home cuff. BMI 34.5 by patient-reported height 5 feet 6 inches. Appears well on video, no distress, speech and orientation normal. Baseline labs from June 20, 2026 reviewed: A1c 5.9%, TSH normal, lipid panel with LDL 132, comprehensive metabolic panel within normal limits.

A. Class I obesity with prediabetes, responding appropriately to GLP-1 receptor agonist therapy at week 8, with 5.7% total body weight loss and tolerable gastrointestinal side effects. No red flag symptoms for pancreatitis or biliary disease. Appropriate for planned dose escalation. Continued behavioral component in place.

P. Continue semaglutide, escalate to 1.0 mg subcutaneously weekly beginning with the August 28 dose. Prescription sent to the patient's pharmacy of record; product is an FDA-approved semaglutide product, not compounded, and this was confirmed with the patient. Injection technique reviewed on video, including site rotation and refrigerated storage per the manufacturer instructions. Counseled to expect a transient increase in nausea for 5 to 7 days after escalation, to eat smaller and lower-fat meals, and to maintain hydration and at least 90 g of protein daily. Instructed to hold the medication and call for severe abdominal pain radiating to the back, repeated vomiting, signs of dehydration, or pregnancy. Repeat A1c and comprehensive metabolic panel at week 12. Telehealth follow-up scheduled September 21, 2026. Telehealth consent on file, signed June 18, 2026. Total visit time 20 minutes. Signed K. Osei, NP, August 24, 2026, 14:22.

Lot numbers, units and injection sites, the fields that protect you

Everything else in a chart can be reconstructed from memory or a schedule. Product identity cannot. If a patient develops a delayed nodule at nine months, or the manufacturer issues a recall, or a board investigator asks where a vial came from, the lot number is the only thing that connects the treatment to the product.

Record the manufacturer, product name, lot number and expiration for every injectable, filler, biostimulator, peptide, IV bag and additive administered. For reconstituted products, record the diluent, the volume, the time of reconstitution and the resulting concentration, because units are meaningless without the dilution. For fillers and biostimulators, record syringe volume used and volume discarded, plus the plane and whether a needle or cannula was used. For devices, record the device name, handpiece or tip, all settings and passes, and the observed skin endpoint.

Site-by-site units are the second irreplaceable field. A total dose tells a reviewer nothing about whether a complication was plausible; a site map tells them exactly what was placed where, which is what an expert compares against the standard of care. A table or a dated, initialed anatomical diagram both work, as long as the numbers add up to the stated total.

Three habits close the loop. Photograph before treatment and at any follow-up where a concern is raised. Note tolerance and the post-treatment observation period, because the absence of an early adverse event is itself a finding. And record the aftercare document by name, so the chart shows which version the patient received.

Charting rules that survive a board complaint

Write the note during or immediately after the visit; contemporaneous notes carry weight that reconstructions do not. Never delete or overwrite an entry. Correct by dated addendum that states what is being corrected and why, leaving the original visible, because clean-looking retroactive edits turn a defensible case into an indefensible one.

Sign every entry with name, credential and date, and identify the ordering prescriber where treatment was delegated. Keep abbreviations conservative, avoid marketing language and opinions about the patient, and record no-shows, refusals and any deviation from the plan with the patient's stated reason. Store notes inside the medical record system rather than in scheduling or point-of-sale software, and confirm your retention period against your state's rule.

The bottom line

SOAP works for aesthetic and wellness visits because it forces a judgment between what the patient says and what you did. The template earns its keep only if Plan carries product, lot, expiration, dilution, units per site and aftercare given, and Assessment contains a real candidacy decision rather than a restatement of the request. Write it contemporaneously, correct it by addendum, and keep it in the medical record. Those habits, not the format, are what hold up under review.

Frequently asked questions

What are the four parts of a SOAP note?

Subjective is what the patient reports, Objective is what you measure and observe, Assessment is your clinical judgment, and Plan is what you did and what happens next. In aesthetic and wellness visits the Plan section carries the treatment record itself, including product, lot number, expiration, dilution, units and injection sites.

Do med spas legally have to keep SOAP notes?

State law and board rules require a medical record for any procedure that constitutes the practice of medicine, and SOAP is simply the most common format for organizing it. The format is optional; the underlying documentation of assessment, treatment given and follow-up is not. Retention periods are set by state and commonly run several years from the last date of service.

Why does the lot number matter in an aesthetic chart note?

The lot number and expiration date tie a specific vial to a specific patient, which is what makes a product recall or an adverse event report traceable. It also evidences that the product came from an authorized source rather than an unapproved supplier. Recording lot, expiration and units per site is standard practice for neurotoxin and filler documentation.

Related templates